Wednesday, May 9, 2018

Amgen Ventures Backs Akili In $55M Funding

Amgen Ventures, the venture capital arm of Thousand Oaks-based Amgen, is one of the investors in a Boston biotech company, Akili Interactive. Akili said Tuesday that it has raised $55M in a Series C funding, which was led by Temasek, and also included Baillie Gifford, Amgen Ventures, M Ventures (the CVC fund of Merck KGaA, Darmstadt, Germany), JAZZ Venture Partners, Canepa Advanced Healthcare Fund, and Brooklands Capital Strategies. Akili is developing digital medicine products aimed at treating cognitive dysfunction, including ADHD, multiple sclerosis, and depression.

---